Methodology: R&D Productivity Ranking
Executive Summary
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.
You may also be interested in...
Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap
Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.
2022 Global Biopharma R&D Productivity And Growth Ranking
The R&D productivity of the top 30 largest biopharma companies decreased slightly from 2021 to 2022 and the sector saw the lowest number of FDA approvals in the past 10 years.
Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.